Baidu
map

Heart:多次流产可增加女性心血管病风险

2015-12-23 徐媛 MedSci原创

目的:本研究旨在评估不管是连续流产还是非连续流产是否会增加女性心血管疾病的风险。 方法:本项回顾性队列性研究收纳了来自1950年到2010年苏格兰阿伯丁孕妇及新生儿数据库的研究数据,所收纳的女性包括不连续流产女性,两次连续流产女性,三次或多次流产女性,完成生育且无流产女性。研究人员统计了受试女性的发病记录,包括缺血性心脏病、脑血管病或其他循环系统疾病。主要结局是患缺血性心脏病、脑血管疾病和循环系

目的:本研究旨在评估不管是连续流产还是非连续流产是否会增加女性心血管疾病的风险。

方法:本项回顾性队列性研究收纳了来自1950年到2010年苏格兰阿伯丁孕妇及新生儿数据库的研究数据,所收纳的女性包括不连续流产女性,两次连续流产女性,三次或多次流产女性,完成生育且无流产女性。研究人员统计了受试女性的发病记录,包括缺血性心脏病、脑血管病或其他循环系统疾病。主要结局是患缺血性心脏病、脑血管疾病和循环系统疾病的发生率。通过灵敏度分析将女性进行划分,分别划分为有一次,两次或三次以上流产。

结果:排除既存在高血压、1型糖尿病、肾脏疾病和循环系统的疾病的女性,研究人员对60105名女性进行了分析,其中有9419名女性无连续流产病史,有940名女性连续两次,有167名女性三次或三次以上连续流产以及有49579名女性没有流产。在多变量分析中,两次或三次连续流产女性最易发生心血管事件,两次连续流产(HRs 1.75 (95% CI 1.22 to 2.52)) 与三次或多次连续流产女性(HR 3.18 (95% CI 1.49 to 6.80))的缺血性心脏病风险明显增加。

结论:有两次或更多流产史的女性,无论是否连续,都可使得女性心血管病风险升高。

原始出处

Wagner MM1, Bhattacharya S2, Visser J1, Hannaford PC3, Bloemenkamp KW1.Association between miscarriage and cardiovascular disease in a Scottish cohort.Heart. 2015 Dec 15;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1644460, encodeId=b612164446034, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 05 15:53:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55105, encodeId=6ec35510564, content=应该普及……, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55104, encodeId=345f551044f, content=好文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55103, encodeId=bb375510376, content=好吧,, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55102, encodeId=feff5510217, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55101, encodeId=287855101c1, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52113, encodeId=48dd5211309, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52112, encodeId=420f52112c1, content=啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49969, encodeId=dc364996948, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:28:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49968, encodeId=19754996835, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:27:00 CST 2015, time=2015-12-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1644460, encodeId=b612164446034, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 05 15:53:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55105, encodeId=6ec35510564, content=应该普及……, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55104, encodeId=345f551044f, content=好文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55103, encodeId=bb375510376, content=好吧,, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55102, encodeId=feff5510217, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55101, encodeId=287855101c1, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52113, encodeId=48dd5211309, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52112, encodeId=420f52112c1, content=啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49969, encodeId=dc364996948, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:28:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49968, encodeId=19754996835, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:27:00 CST 2015, time=2015-12-28, status=1, ipAttribution=)]
    2016-01-09 medsic

    应该普及……

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1644460, encodeId=b612164446034, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 05 15:53:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55105, encodeId=6ec35510564, content=应该普及……, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55104, encodeId=345f551044f, content=好文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55103, encodeId=bb375510376, content=好吧,, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55102, encodeId=feff5510217, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55101, encodeId=287855101c1, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52113, encodeId=48dd5211309, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52112, encodeId=420f52112c1, content=啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49969, encodeId=dc364996948, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:28:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49968, encodeId=19754996835, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:27:00 CST 2015, time=2015-12-28, status=1, ipAttribution=)]
    2016-01-09 medsic

    好文章,

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1644460, encodeId=b612164446034, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 05 15:53:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55105, encodeId=6ec35510564, content=应该普及……, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55104, encodeId=345f551044f, content=好文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55103, encodeId=bb375510376, content=好吧,, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55102, encodeId=feff5510217, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55101, encodeId=287855101c1, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52113, encodeId=48dd5211309, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52112, encodeId=420f52112c1, content=啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49969, encodeId=dc364996948, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:28:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49968, encodeId=19754996835, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:27:00 CST 2015, time=2015-12-28, status=1, ipAttribution=)]
    2016-01-09 medsic

    好吧,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1644460, encodeId=b612164446034, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 05 15:53:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55105, encodeId=6ec35510564, content=应该普及……, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55104, encodeId=345f551044f, content=好文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55103, encodeId=bb375510376, content=好吧,, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55102, encodeId=feff5510217, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55101, encodeId=287855101c1, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52113, encodeId=48dd5211309, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52112, encodeId=420f52112c1, content=啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49969, encodeId=dc364996948, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:28:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49968, encodeId=19754996835, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:27:00 CST 2015, time=2015-12-28, status=1, ipAttribution=)]
    2016-01-09 medsic

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1644460, encodeId=b612164446034, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 05 15:53:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55105, encodeId=6ec35510564, content=应该普及……, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55104, encodeId=345f551044f, content=好文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55103, encodeId=bb375510376, content=好吧,, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55102, encodeId=feff5510217, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55101, encodeId=287855101c1, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52113, encodeId=48dd5211309, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52112, encodeId=420f52112c1, content=啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49969, encodeId=dc364996948, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:28:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49968, encodeId=19754996835, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:27:00 CST 2015, time=2015-12-28, status=1, ipAttribution=)]
    2016-01-09 medsic

    额…

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1644460, encodeId=b612164446034, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 05 15:53:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55105, encodeId=6ec35510564, content=应该普及……, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55104, encodeId=345f551044f, content=好文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55103, encodeId=bb375510376, content=好吧,, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55102, encodeId=feff5510217, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55101, encodeId=287855101c1, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52113, encodeId=48dd5211309, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52112, encodeId=420f52112c1, content=啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49969, encodeId=dc364996948, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:28:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49968, encodeId=19754996835, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:27:00 CST 2015, time=2015-12-28, status=1, ipAttribution=)]
    2016-01-05 xyfg98

    值得关注

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1644460, encodeId=b612164446034, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 05 15:53:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55105, encodeId=6ec35510564, content=应该普及……, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55104, encodeId=345f551044f, content=好文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55103, encodeId=bb375510376, content=好吧,, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55102, encodeId=feff5510217, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55101, encodeId=287855101c1, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52113, encodeId=48dd5211309, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52112, encodeId=420f52112c1, content=啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49969, encodeId=dc364996948, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:28:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49968, encodeId=19754996835, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:27:00 CST 2015, time=2015-12-28, status=1, ipAttribution=)]
    2016-01-05 xyfg98

    啊?

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1644460, encodeId=b612164446034, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 05 15:53:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55105, encodeId=6ec35510564, content=应该普及……, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55104, encodeId=345f551044f, content=好文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55103, encodeId=bb375510376, content=好吧,, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55102, encodeId=feff5510217, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55101, encodeId=287855101c1, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52113, encodeId=48dd5211309, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52112, encodeId=420f52112c1, content=啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49969, encodeId=dc364996948, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:28:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49968, encodeId=19754996835, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:27:00 CST 2015, time=2015-12-28, status=1, ipAttribution=)]
    2015-12-28 wzf990214

    赞一个

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1644460, encodeId=b612164446034, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Sat Nov 05 15:53:00 CST 2016, time=2016-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55105, encodeId=6ec35510564, content=应该普及……, beContent=null, objectType=article, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55104, encodeId=345f551044f, content=好文章,, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55103, encodeId=bb375510376, content=好吧,, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55102, encodeId=feff5510217, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55101, encodeId=287855101c1, content=额…, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 22:02:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52113, encodeId=48dd5211309, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52112, encodeId=420f52112c1, content=啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Jan 05 13:28:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49969, encodeId=dc364996948, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:28:00 CST 2015, time=2015-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49968, encodeId=19754996835, content=不错哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Mon Dec 28 15:27:00 CST 2015, time=2015-12-28, status=1, ipAttribution=)]
    2015-12-28 wzf990214

    不错哦

    0

相关资讯

长城会 2014:中国原创研究:心血管死亡使国人寿命减5岁

防控高血压是预防国人因心血管病过早死亡的重要策略 首都医科大学附属北京安贞医院赵冬教授等发现,心血管病死亡对我国人群寿命有很大影响,导致我国人群平均寿命缩短近5年。如其他疾病相关死亡率保持不变,若想将我国人群寿命延长1年,心血管病死亡率至少要从当前水平降低27.4%。(Biomed Environ Sci.2014,27:162) 赵冬教授指出,由于我国农村地区因心血管病死

小知识:无症状人群如何评估心血管病危险?

当评估无心血管病症状受检者心血管病危险时,C反应蛋白(CRP)、糖化血红蛋白(HbA1c)等各种心血管病的“新型”危险评估指标以及心血管无创检测技术如何合理应用? 应用“新型”危险评估指标评估无症状人群心血管危险的相关建议 CRP 对满足下列条件的人群建议测定CRP水平:年龄≥50岁的男性或≥60岁的女性,低密度脂蛋白胆固醇(LDL-C)低于3.36 mmol/L;未接受降脂、激素替代或

我国心血管病流行趋势的新特点

作者:刘静(首都医科大学附属北京安贞医院 北京市心肺血管疾病研究所流行病研究室)心血管病是我国人群的首要死亡原因,已占总死亡的40%。有关心血管病流行程度和变化趋势的数据对制定我国心血管病防治策略、确定防治的重点方向具有重要意义。近期研究反映了我国心血管病流行趋势的几个新特点,尤其值得关注。一、缺血性心血管病的死亡率和发病率呈明显上升趋势来自全国疾病监测系统的监测数据显示,我国心血管病总死亡率从2

徐巍巍:降压,你还在限盐吗?

近日,有新证据指出,与食盐相比,糖类或更易增加高血压及心血管病的发生风险。 心血管病是发达国家中导致过早死亡的首位原因,高血压则是心血管病的主要危险因素。既往我们一直在通过限盐控制高血压,然而,对于这一预防策略,是存在争议的,现已有相关研究证实,通过限盐降低血压的效果甚微。 近期一项纳入100000例患者的研究指出,与每日钠盐摄入<3g或>6g者相比,每日钠盐摄入为3~6g者,死亡及心

Circulation:预防心血管病应从娃娃抓起(STRIP研究)

芬兰一项名为STRIP的纵向随机研究显示,若从婴儿时期就通过学校或父母对其实施健康饮食生活计划,则在其15~20 岁时,患代谢综合征风险将下降41%。 研究纳入1062例婴幼儿,分为饮食生活干预组和不干预组。在干预组实施限盐计划,并推荐全谷物、水果及蔬菜饮食,并在其8岁后,对其初步普及戒烟知识并鼓励多进行体力活动。 在受试者15~20岁时,干预组代谢综合征患病率为 6.0%

Ann Intern Med:久坐有损健康 不管体力活动状况如何

坐着等死?这句戏谑其实很严肃。近期一项纳入47项研究的荟萃分析显示,不管体力活动状况如何,久坐有损健康。 研究者发现,久坐可以增加24%的全因死亡风险,17%之多的心血管死亡风险,14%的心血管病的发生风险,和13%的癌症发生风险和91%的2型糖尿病的发生风险。此外,静坐时间越久,患病和死亡风险越高。 久坐与心血管病的关系可追溯到上世纪50年代,当时有学者注意到,在英国伦敦

Baidu
map
Baidu
map
Baidu
map